Low-Dose High-Frequency Chemotherapy for Small-Cell Lung Cancer
Author Information
Author(s): LE James, NH Gower, RM Rudd, SG Spiro, PG Harper, CW Trask, M Partridge, M-C Ruiz De Elvira, RL Souhami
Primary Institution: University College London Medical School
Hypothesis
Major dose reduction might lessen the acute toxicity of chemotherapy without worse survival provided that the dose intensity (DI) of treatment was maintained.
Conclusion
The low-dose high-frequency regimen provides similar response rates and survival compared to conventional chemotherapy but does not offer significant benefits in toxicity or quality of life.
Supporting Evidence
- The overall response rate was 58.9% for the 10/11 day regimen and 44.9% for the 3 weekly regimen.
- Median survival was similar in both arms at 6.4 months for the 10/11 day arm and 5.8 months for the 3 weekly arm.
- Survival at 1 year was 9.9% for the 10/11 day arm and 8.9% for the 3 weekly arm.
- Leucopenia was more frequent with the 10/11 day regimen.
Takeaway
This study looked at a new way to give chemotherapy to lung cancer patients. They found that giving smaller doses more often worked just as well as the usual method.
Methodology
Patients were randomized to receive either a conventional 3-weekly regimen or a low-dose/high-frequency regimen of the same drugs.
Limitations
The study's sample size may not exclude a survival difference smaller than 12% at 1 year for either regimen.
Participant Demographics
Patients had extensive small-cell lung cancer with poor prognostic features, aged 75 years or less.
Statistical Information
Confidence Interval
95% CI for overall response rate: 10/11 day arm 47.9-69.2, 3 weekly arm 35.0-55.5.
Statistical Significance
p>0.05
Want to read the original?
Access the complete publication on the publisher's website